US tariff policy uncertainty on pharma products
While current tariffs exempt pharma, potential changes under Section 232 could impact API exports; management noted contracts are largely FOB but impact unclear.
high · analyst_questionAarti Pharmalabs Limited — Q1 FY26
Aarti Pharmalabs reported Q1 FY26 consolidated revenue of ₹386 crore, down ~30% YoY due to Ganesh Polychem deconsolidation and a planned shutdown.
neutral
medium
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lumpy CDMO revenue recognition
CDMO revenue is back-end loaded and lumpy due to multi-stage manufacturing; Q1 performance may not be indicative of full-year trajectory.
medium · management_commentaryGanesh Polychem joint venture ramp-up risk
GPL plant underwent shutdown for modifications; restart in July may delay contribution to profitability in FY26.
medium · management_commentaryCapacity utilization drag from new greenfield plant
Atali greenfield plant will have higher opex initially; full utilization may take until end of FY26, pressuring near-term margins.
medium · management_commentary